CBL-514 Isn’t a Peptide: How It Compares to AOD-9604 and Other Fat-Loss Peptides
The Peptide Effect · Oct 20, 2026 · 27:22
The Peptide Effect · Oct 20, 2026 · 27:22
Listen in the Podli app 🎧
Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.
CBL-514 is making waves in fat-reduction research, but despite showing up in peptide conversations, it isn’t a peptide. In this episode of The Peptide Effect, we explain what it is, how it differs from AOD-9604, and how peptides like tesamorelin, semaglutide, tirzepatide, and retatrutide fit into the discussion. Discover the differences between targeted fat reduction, visceral fat reduction, and overall weight loss—and what the research actually supports.
